Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion

Scott Wadler, Della Makower, Caroline Clainmont, Paula Lambert, Karen Fehn, Mario Sznol

Research output: Contribution to journalArticlepeer-review

117 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion'. Together they form a unique fingerprint.

Medicine & Life Sciences